- Alumis Inc. (ALMS, Financial) successfully completes merger with ACELYRIN, Inc., creating a leading biopharma company.
- ACELYRIN stockholders receive 0.4814 shares of Alumis common stock per ACELYRIN share.
- Merger extends Alumis' cash runway into 2027, strengthening its financial position.
Alumis Inc. (NASDAQ: ALMS) has finalized its merger with ACELYRIN, Inc., establishing a dominant clinical-stage biopharmaceutical company focused on developing next-generation therapies for immune-mediated diseases. Under the merger conditions, ACELYRIN stockholders are granted 0.4814 shares of Alumis common stock for each ACELYRIN share owned. Post-merger, ACELYRIN's stock has been delisted from the NASDAQ Global Select Market.
This strategic merger significantly bolsters Alumis' balance sheet, providing the combined entity with a cash runway extending into 2027. The new company plans to advance its late-stage portfolio through several planned key data readouts, leveraging its enhanced financial stability.
Alumis was advised by Morgan Stanley & Co. LLC, with Cooley LLP as its legal counsel, whereas Guggenheim Securities, LLC served as the financial advisor to ACELYRIN, supported by legal counsel from Fenwick & West LLP and Paul Hastings LLP.
Alumis is committed to advancing its pipeline, which includes targeted therapies such as ESK-001 and A-005, and lonigutamab, enhancing treatment options for systemic immune-mediated disorders and other diseases. For more information, visit the official Alumis website or follow their updates on LinkedIn or X.
